{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-036876","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2024-12-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.443744+00:00","generated_at":"2026-05-29T06:17:39.374678+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Zevra Therapeutics Announces Departure of Chief Development Officer and Chief Scientific Officer","bullets":["Christal Mickle, Chief Development Officer and Co-Founder, notified of departure effective Dec. 6, 2024.","Sven Guenther, Ph.D., Chief Scientific Officer, departing Zevra effective Dec. 23, 2024.","Development and scientific functions consolidated under Chief Medical Officer Adrian Quartel, M.D.","In-house drug discovery discontinued; laboratory facilities in Iowa and Virginia to close.","Changes include elimination of positions in CMC and Clinical Development as part of strategic plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-036876","json":"https://secwatch.observer/filing/0001437749-24-036876.json","markdown":"https://secwatch.observer/filing/0001437749-24-036876.md","text":"https://secwatch.observer/filing/0001437749-24-036876.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924036876/0001437749-24-036876-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924036876/zvra20241204_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-29T06:17:39.374678+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}